The 98th Annual Meeting of the Japanese Gastric Cancer Association

Call for Abstracts

Note

All presentations in the APGCC × JGCA Joint Session are by invitation only, and abstract submissions are not open to the public.
Abstracts from overseas presenters will be accepted collectively through our co-hosted congress, JGCA2026.
Submitted abstracts will be officially recognized as part of the programs of both APGCC2026 and JGCA2026, and will be counted toward the official participation record of both congresses.

Abstract Submission Period

Abstracts for oral, poster

Wednesday, 9 July, 12:00 PM (JST) – Wednesday, 27 August, 12:00 PM (JST)

Abstract Submission

You may revise or delete your submitted abstract as many times as necessary before the submission deadline.
Please note that no changes can be made after the deadline.

To change or update your registration information, please click the “Confirmation / Modification” button.

This system is confirmed to work with Google Chrome, Microsoft Edge, and Safari.
Please do not use any other browser.

Safari is supported on version 2.0.3 (417.9.2) or later. Older versions are not compatible.

Presentation Style/Categories

Please select the most appropriate category for your presentation.

Main session style

Oral presentation

Main session category

Symposium

Frontline of New Drug Development – Expectations for Gastric Cancer

The global landscape of pharmaceutical development is undergoing significant transformation. In addition to traditional small molecule drugs and antibody therapeutics, a wide variety of new modalities – including antibody-drug conjugates, T cell engagers, CAR-T therapies (regenerative medicine), and medium-sized molecule drugs – are being developed for various cancer types.
This session will discuss the latest trends and future prospects of drugs and seeds that are currently under development or may be developed for gastric cancer.

Cutting-Edge Robotic Surgery: The Next Frontier

Robotic surgery has rapidly evolved from experimental systems to mainstream surgical platforms, especially in gastrointestinal oncology. This session will explore the latest technological advancements, clinical outcomes, and future directions of robotic-assisted procedures. By gathering leading experts, we aim to discuss current challenges, integration into standard care, and how robotic innovation continues to redefine surgical precision and patient safety.

Panel discussion

Present and future perspective of AI/Digital Pathology

Driven by the recent progress of digital technologies and artificial intelligence, pathology is undergoing a period of significant advancement. With the convergence of digital pathology, image recognition programs empowered by machine/deep learning, and bioinformatics developed through genomic medicine, we are beginning to envision a new future. We would like to deepen our discussion by inviting pathologists and researchers with expertise in this field to share the latest insights.

Surgical Strategies in Reconstruction After Proximal Gastrectomy: Balancing Function and Safety

Proximal gastrectomy (PG) has gained renewed attention as a function-preserving surgical option for upper-third gastric cancer. However, the choice of reconstruction method remains controversial due to the need to balance postoperative function, complication risks, and long-term quality of life. This session will focus on the current strategies for reconstruction after PG, including techniques such as esophagogastrostomy, double tract reconstruction, and jejunal interposition. Experts will present recent data, technical tips, and comparative outcomes to identify the most appropriate approach for various clinical situations. Through interactive discussion, we aim to clarify the decision-making process and promote consensus on optimizing both functional outcomes and surgical safety.

Workshop

Impact of AI on managing gastric cancer in endoscopy, pathology, and surgery

Artificial intelligence (AI)-based devices and technologies are being gradually introduced into clinical practice across various medical fields. Several AI-assisted tools designed to aid in the management of gastric cancer have already been commercialized. In this session, we invite presentations on novel approaches and the development of AI in various areas, such as endoscopy, pathology, and surgery, as well as effective utilization strategies for existing AI-based devices in managing gastric cancer.

General Presentation style

Oral presentation, Poster presentation (Paper style)
If you are submitting a general abstract, we actively encourage Oral presentations and would be grateful if you would consider submitting one.

General Presentation category
1Epidemiology
2Molecular biology
3Pathology
4Genomics
5Translational research
6Biomarker
7Tumor microenvironment
8AI
9Endoscopic therapy
10Endoscopic diagnosis
11Imaging diagnosis
12H. pylori
13Progression of gastric cancer
14Rare metastasis / Micrometastasis
15Intraoperative frozen section
16Cancer stem cell
17Clinical pathology
18Prognostic factor
19Precision medicine
20Clinical study
21Chemotherapy
22Neoadjuvant chemotherapy
23Adjuvant chemotherapy
24Second-line chemotherapy
25Third-line chemotherapy
26Intraperitoneal chemotherapy
27Molecular targeted therapy
28Immunotherapy
29Radiation therapy
30conversion surgery
31Surgery
32Laparoscopic surgery
33Robot surgery
34Function-preserving surgery
35Cytoreductive surgery
36LECS
37Surgical navigation
38Postoperative functional assessment
39Postgastrectomy syndrome
40Perioperative management
41Postoperative complications
42ERAS
43Navigation Surgery
44Peritoneal dissemination
45CART
46Stent placement
47Liver metastasis
48Recurrence
49Early gastric cancer
50Advanced gastric cancer
51Scirrhous gastric cancer
52Gastric stump carcinoma
53Multiple gastric cancers
54Gastric tube cancer
55Esophago-gastric junction cancer
56Gastric cancer in elderly patients
57AFP-producing gastric cancer
58EBV-related gastric cancer
59Gastrointestinal stromal tumor
60Malignant lymphoma
61Gastric neuroendocrine tumor
62Guidelines
63Clinical pathway
64Postoperative surveillance
65Long-term survival case after chemotherapy
66NST
67Outcome
68QOL assessment
69Cachexia
70Nutrition
71Obesity
72Case report
73Japanese Classification of Gastric Carcinoma
74Multidisciplinary treatment
75Palliative therapy
76Team approach
77Patient Adovocacy
78MDT conference
79Medical cooperation
80Oral care
81EFTR
82Oligometastasis
83Others

About the Best Poster Session

About the Poster Session for the Best Presentation The best poster abstracts will be selected from among the general abstract (poster) submissions at after a rigorous review process.

Abstract Acceptance or Rejection

Please note that the acceptance or rejection of abstracts, as well as the presentation format, is at the sole discretion of the Congress President.

Travel Grant

The Travel Grant will be awarded to abstracts recognized as outstanding.
The selection process is entirely entrusted to the discretion of the Congress President.

Abstract Submission

Language for abstract

English

Language for presentation

English

Language for presentation slides

English

The number of characters

Title: Up to 120 characters including spaces (approximately 20-24 words)
Abstract: Up to 2,000 characters including spaces (approximately 330-400 words)

* Please note that the abstract will be published as submitted. We kindly ask you to carefully check for any typographical or grammatical errors before submission.

Conflict of Interest Disclosure

The author is required to report applicable COI (Conflict of Interest) by completing the “Conflict of Interest Disclosure” part in the Abstract Submission process.

Abstract Submission

You may revise or delete your submitted abstract as many times as necessary before the submission deadline.
Please note that no changes can be made after the deadline.

To change or update your registration information, please click the “Confirmation / Modification” button.

This system is confirmed to work with Google Chrome, Microsoft Edge, and Safari.
Please do not use any other browser.

Safari is supported on version 2.0.3 (417.9.2) or later. Older versions are not compatible.

Inquiries

Secretariat of the 98th Annual Meeting of the Japanese Gastric Cancer Association
c/o Japan Convention Services, Inc.
14F Daido Seimei Kasumigaseki Bldg.
1-4-2, Kasumigaseki, Chiyoda-ku,
Tokyo 100-0013, Japan
E-mail: endai-98jgca[A]convention[D]co[D]jp( Please change [A] to @ and [D] to . )

page top